Vaccines and methods of using the same to treat wnt-related cancer

Abstract

The present disclosure provides a composition comprising a nucleic acid sequence encoding from about 1 to about 100 amino acid sequences that are tumor-specific antigens, wherein at least one tumor-specific antigen is an amino acid sequence associated with a WNT pathway. In some embodiments, the nucleic acid sequence encodes from about 20 to about 60 tumor-specific antigens; wherein from about 1 to about 8 tumor-specific antigens are chosen from one or a combination of: WNT, CTNNB1, AXIN1, AXIN2, APC, CK1, and GSK3B. Also provided is a cell comprising any one or plurality of compositions disclosed herein. Also provided is a pharmaceutical composition comprising: (i) a therapeutically effective amount of one or a plurality of compositions as disclosed herein; and (ii) a pharmaceutically acceptable carrier. Also provided is a method of treating cancer in a subject in need thereof comprising administering to the subject: (i) a pharmaceutical composition comprising a nucleic acid sequence encoding about twenty or more neoantigens or epitopes specific for neoantigens; or (ii) a pharmaceutical composition disclosed herein. In some embodiments, the method further comprises administering to the subject a therapeutically effective amount of a checkpoint inhibitor.

Dependencies are inferred from the claim text.